Top Story

Active surveillance not appropriate for all patients with intermediate-risk prostate cancer

February 25, 2015

Although active surveillance is acceptable for low-risk prostate cancers, the strategy may be risky for patients with intermediate-risk disease, according to study results presented at the Genitourinary Cancers Symposium.

In a single-institution study, Andrew Loblaw, MD, radiation oncologist at Sunnybrook Health Sciences Centre in Toronto, and colleagues observed an association between active surveillance and shorter survival among some patients with intermediate-risk disease.

Emmanuel S. Antonarakis, MBBCh Meeting News Coverage

AR-V7 status not associated with taxane chemotherapy resistance in advanced prostate cancer

February 24, 2015
Men with metastatic castration-resistant prostate cancer demonstrated similar responses to taxane chemotherapy regardless of whether they had androgen receptor…
Meeting News Coverage

Testicular cancer may elevate risk for intermediate-or high-risk prostate cancer

February 23, 2015
Although risk remains low, men who have had testicular cancer appear more likely to develop intermediate- or high-risk prostate cancer, according to study results…
Meeting News Coverage

Incidence of higher-risk prostate cancer increases since 2011

February 23, 2015
The number of men diagnosed with at least intermediate-risk prostate cancer increased by 6% from 2011 to 2013, according to study results presented at the Genitourinary…
CME
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
Meeting News Coverage Video
Docetaxel plus ADT improved OS in metastatic prostate cancer th

Docetaxel plus ADT improved OS in metastatic prostate cancer

June 24, 2014
CHICAGO — Donald L. Trump, MD, FACP, president and CEO at Roswell Park Cancer Institute and HemOnc Today
More »
CME
Hot melanoma

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates - Monograph

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
Andrew Loblaw, MD Meeting News Coverage

Active surveillance not appropriate for all patients with intermediate-risk prostate cancer

February 25, 2015
Although active surveillance is acceptable for low-risk prostate cancers, the strategy may be risky for patients with intermediate-risk disease…
Emmanuel S. Antonarakis, MBBCh Meeting News Coverage

AR-V7 status not associated with taxane chemotherapy resistance in advanced prostate cancer

February 24, 2015
Men with metastatic castration-resistant prostate cancer demonstrated similar responses to taxane chemotherapy regardless of whether they had…
Meeting News Coverage

Testicular cancer may elevate risk for intermediate-or high-risk prostate cancer

February 23, 2015
Although risk remains low, men who have had testicular cancer appear more likely to develop intermediate- or high-risk prostate cancer, according to…
Meeting News Coverage

Incidence of higher-risk prostate cancer increases since 2011

February 23, 2015
The number of men diagnosed with at least intermediate-risk prostate cancer increased by 6% from 2011 to 2013, according to study results presented…
In the Journals

Extra-virgin olive oil ingredient rapidly induces cancer cell death

February 19, 2015
Oleocanthal, an ingredient found in extra-virgin olive oil, induces cancer cell death without harming noncancerous cells, according to study…
Navi B. Babak, MD In the Journals

Incident cancer linked to increased short-term stroke risk

February 17, 2015
Patients with a new cancer diagnosis have an elevated risk for subsequent stroke, according to study results.Babak Navi, MD, assistant professor of…
thumbnail for video 4040822599001 Video

Routine PSA screening for most men not ready for ‘prime time’

February 10, 2015
Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, president of Levine Cancer Institute at Carolinas HealthCare System and HemOnc Today's Chief…
Charles J. Ryan, MD In the Journals

Abiraterone acetate plus prednisone improved OS in certain patients with prostate cancer

February 6, 2015
The addition of abiraterone acetate to prednisone significantly improved survival and delayed disease progression among men with metastatic…
In the Journals

Neoadjuvant vs. adjuvant ADT yields similar survival rates for prostate cancer

February 3, 2015
Patients with intermediate- or high-risk prostate cancer demonstrated similar biochemical relapse-free survival, distant metastasis-free survival and…
In the JournalsPerspective

Targeted fusion-guided biopsy improved detection of high-risk prostate cancers

January 27, 2015
Targeted magnetic resonance/ultrasound fusion prostate biopsy detected significantly more cases of high-risk prostate cancers than standard…
More Headlines »